2025
OP-35: Does a tool designed to measure potentially preventable chemotherapy toxicities do so effectively?
Huey R, Zafar A, Le P, Sanchez N, Patlovich K, Olivieri N, Singhi E, Rivera J, Roux R, Adelson K. OP-35: Does a tool designed to measure potentially preventable chemotherapy toxicities do so effectively? Journal Of Clinical Oncology 2025, 43: 1538-1538. DOI: 10.1200/jco.2025.43.16_suppl.1538.Peer-Reviewed Original ResearchQualifying diagnosisRates of emergency department visitsSecondary diagnosisOutpatient chemotherapy treatmentQuality of careEmergency department visitsCenters for MedicareChemotherapy treatmentRetrospective review of patientsMeasures of qualityDepartment visitsUniversity of Texas MD Anderson Cancer CenterMD Anderson Cancer CenterPreventive visitsChemotherapy-related complicationsReview of patientsAnti-cancer therapyComplication of chemotherapy treatmentDiagnosis groupsCancer CenterChemotherapy toxicityPatient 1Retrospective reviewVisitsNational Quality FoundationThe Incidence and Significance of Delayed Bleeding Events After Lower Extremity Revascularization in Patients with Advanced Peripheral Arterial Disease
Hundito A, Wells N, Tuttle M, Alameddine D, Huttler J, Slade M, Strosberg D, Lee A, Guzman R, Ochoa Chaar C. The Incidence and Significance of Delayed Bleeding Events After Lower Extremity Revascularization in Patients with Advanced Peripheral Arterial Disease. Journal Of Vascular Surgery 2025 PMID: 40187383, DOI: 10.1016/j.jvs.2025.03.394.Peer-Reviewed Original ResearchLower extremity revascularizationPeripheral arterial diseaseBleeding eventsBleeding episodesAdvanced peripheral arterial diseaseArtery diseaseAntithrombotic therapyExtremity revascularizationRetrospective review of patientsIncidence of bleeding eventsAssociated with worse overall outcomesDelayed bleeding eventsDiscontinuation of ASAPrescription of antithrombotic therapyRecurrent bleeding episodesReview of patientsChronic renal insufficiencyEnd-stage renal diseaseOutcomes of patientsTertiary care centerHistory of smokingRecurrent bleeding eventsLong-term outcomesCoronary artery diseaseLower-extremity revascularizationRemoving Rehabilitation Barriers to Early Mobility in the Intensive Care Unit for Adult Patients With Femoral Arterial and Hemodialysis Catheters
Bennett K, Carbone A, Ferrante L, Cooper D, Foley B. Removing Rehabilitation Barriers to Early Mobility in the Intensive Care Unit for Adult Patients With Femoral Arterial and Hemodialysis Catheters. Journal Of Acute Care Physical Therapy 2025, 16: 49-54. DOI: 10.1097/jat.0000000000000251.Peer-Reviewed Original ResearchEdge of bedIntensive care unitBarriers to mobilityLevel of mobilityMaximum level of mobilityBed to chairCare unitMobility of patientsInterprofessional participantsInterprofessional teamTherapeutic exerciseRehabilitation barriersPractice changeNo adverse eventsEarly mobilizationProspective review of patientsBed restAdverse eventsProspective reviewAdverse event ratesHD cathetersReview of patientsAdult patientsEvent ratesStandard protocolEvolution of EEG Findings in Patients with Acute Brain Injury
Narrett J, Byrnes M, Gilmore E, Hirsch L, Punia V, Sivaraju A. Evolution of EEG Findings in Patients with Acute Brain Injury. Neurocritical Care 2025, 1-8. PMID: 40038178, DOI: 10.1007/s12028-025-02227-y.Peer-Reviewed Original ResearchAcute brain injuryLateralized rhythmic delta activityLateralized periodic dischargesRhythmic delta activityEEG findingsContinuous electroencephalographyPeriodic dischargesDelta activityEEG patternsRetrospective chart review of patientsChart review of patientsSporadic epileptiform dischargesFollow-up EEGReview of patientsBrain injuryGeneralized periodic dischargesRetrospective chart reviewAcute symptomatic seizuresAntiseizure medication treatmentEvolution of EEG patternsConclusionsIn patientsElectrographic seizuresNeurological outcomeBackgroundIncreasing useElectroclinical seizuresThe Natural History of Congenital Hepatic Hemangiomas
Ostertag-Hill C, Fevurly R, Kulungowski A, Christison-Lagay E, McGuire A, Rialon K, Duggan E, Murillo R, Zurakowski D, Staffa S, Alomari A, Kozakewich H, Al-Ibraheemi A, Fishman S, Dickie B. The Natural History of Congenital Hepatic Hemangiomas. The Journal Of Pediatrics 2025, 281: 114523. PMID: 40023218, DOI: 10.1016/j.jpeds.2025.114523.Peer-Reviewed Original ResearchCongenital hepatic hemangiomasCongenital HHHepatic hemangiomaMedical therapyRetrospective review of patientsNatural historyReview of patientsKaplan-Meier curvesMonths of ageCongenital hemangiomaRetrospective reviewClinical presentationRespiratory failureClinical behaviorHeart failureHH volumeHistological findingsEarly recognitionResidual volumeGeneralized estimating equationsIncorrect diagnosisHemangiomaPatientsNo differenceRate of involutionEndovascular Embolization versus Observation of Congenital Renal Arteriovenous Malformations: A Retrospective Study
Hufnagle J, Fish A, Schlachter T. Endovascular Embolization versus Observation of Congenital Renal Arteriovenous Malformations: A Retrospective Study. Journal Of Vascular And Interventional Radiology 2025, 36: 988-993.e1. PMID: 39938714, DOI: 10.1016/j.jvir.2025.02.001.Peer-Reviewed Original ResearchCongenital renal arteriovenous malformationRenal arteriovenous malformationType I AVMArteriovenous malformationsEndovascular embolizationAdverse eventsImaging review of patientsReview of patientsArteriovenous malformation ruptureFollow-up dataYakes classificationTransarterial embolizationEmbolization groupPresenting symptomsPatient demographicsRetrospective studyProcedural imagingImaging reviewEmbolizationPatientsObservation groupMalformationsComplicationsVessel sizeNephrectomySex differences in patterns of cardiovascular referral in patients with Marfan, Ehlers-Danlos, and Loeys-Dietz syndromes
Waldron C, Nasir A, Wang K, Chou A, Erez E, Vallabhajosyula P, Assi R. Sex differences in patterns of cardiovascular referral in patients with Marfan, Ehlers-Danlos, and Loeys-Dietz syndromes. JTCVS Open 2025, 24: 1-15. PMID: 40309713, PMCID: PMC12039419, DOI: 10.1016/j.xjon.2025.01.002.Peer-Reviewed Original ResearchCardiothoracic surgeryConnective tissue diseaseFemale patientsEhlers-DanlosAortic pathologyLoeys-DietzCardiovascular medicineMale patientsTissue diseaseRetrospective review of patientsReview of patientsLoeys-Dietz syndromeDiagnosis of MFSReferral ratesSex differencesMFS patientsRetrospective reviewAortic diseaseRate of referralSurgeryPatientsMedical recordsClinical diagnosisElectronic medical recordsObjective diagnosisAnalgesic Quality Improvement in Paravertebral Blocks for Pediatric Nuss Procedure: An Exploratory Report on the Effects of Perineural Combined Glucocorticoids
Donham R, Jin E, Caty M, Thomas D, Yuan C, Hollingsworth K, Zhang X, Yanez N, Li J. Analgesic Quality Improvement in Paravertebral Blocks for Pediatric Nuss Procedure: An Exploratory Report on the Effects of Perineural Combined Glucocorticoids. Journal Of Pain Research 2025, 18: 489-496. PMID: 39895814, PMCID: PMC11784254, DOI: 10.2147/jpr.s502600.Peer-Reviewed Original ResearchPostoperative opioid consumptionContinuous thoracic paravertebral blockMorphine milligram equivalentsThoracic paravertebral blockParavertebral blockOpioid consumptionNuss procedureDexamethasone sodium phosphateCombined glucocorticoidPain scoresDecreased postoperative opioid consumptionOral morphine milligram equivalentsMethylprednisolone acetateContinuous paravertebral blockPostoperative opioid usagePectus excavatum repairReview of patientsHospital length of stayAcademic children's hospitalLength of stayOpioid usageMilligram equivalentsElectronic health record reviewPlain ropivacaineWound dehiscence
2024
Transverse versus Vertical Incision in the Surgical Management of Placenta Accreta Spectrum
Oberlin A, Yoh K, Overton E, Booker W, Ilagan J, Sassine D, Diggs A, Laifer-Narin S, Cimic A, Ring L, Sheikh M, St. Clair C, Hou J, de Meritens A, Wright J, D'Alton M, Chang C, Mourad M, Khoury-Collado F. Transverse versus Vertical Incision in the Surgical Management of Placenta Accreta Spectrum. American Journal Of Perinatology 2024, 42: 1200-1205. PMID: 39566520, DOI: 10.1055/a-2479-2604.Peer-Reviewed Original ResearchPlacenta accreta spectrumPacked red blood cellsTransverse skin incisionVertical skin incisionTransverse incisionSkin incisionGeneral anesthesiaSurgical management of placenta accreta spectrumManagement of placenta accreta spectrumSeverity of placenta accreta spectrumUnits of packed red blood cellsMidline vertical skin incisionRetrospective review of patientsRate of intraoperative complicationsIncidence of surgical complicationsVertical incisionScheduled surgeryAnterior uterine wallCompare maternal outcomesReview of patientsRate of transfusionAssociated with lower conversionUterine incisionIntraoperative outcomesMaternal outcomesAssociation Between Chemotherapy-Induced Peripheral Neuropathy and Low Anterior Resection Syndrome
Linhares S, Schultz K, Coppersmith N, Esposito A, Leeds I, Pantel H, Reddy V, Mongiu A. Association Between Chemotherapy-Induced Peripheral Neuropathy and Low Anterior Resection Syndrome. Cancers 2024, 16: 3578. PMID: 39518019, PMCID: PMC11545659, DOI: 10.3390/cancers16213578.Peer-Reviewed Original ResearchLow anterior resection syndromeChemotherapy-induced peripheral neuropathyAnterior resection syndromeSystemic therapyRectal cancerPeripheral neuropathyAssociated with low anterior resection syndromeRetrospective review of patientsPlatinum-based chemotherapy agentsLow anterior resectionReview of patientsSphincter-preserving surgeryRectal cancer treatmentNeoadjuvant chemoradiationTumor distanceAnal vergeAnterior resectionRetrospective reviewChemotherapy-inducedChemotherapy agentsSide effectsCancer treatmentDebilitating conditionPatientsCIPNCriteria for PAVM Reintervention
Fish A, Knight E, Henderson K, Pollak J, Schlachter T. Criteria for PAVM Reintervention. Journal Of Clinical Medicine 2024, 13: 6104. PMID: 39458055, PMCID: PMC11508501, DOI: 10.3390/jcm13206104.Peer-Reviewed Original ResearchParadoxical embolismRetrospective review of patientsReview of patientsModern embolization techniquesRetrospective reviewEmbolization techniquesReinterventionScreening intervalEmbolizationLifetime prevalence ratesPatientsRecurrencePAVMsHemoptysisSpontaneous eventsPrevalence ratesCenters of excellenceReperfusionCriteriaFactor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease
Allen C, Heskel M, Butt A, Tormey C, Pine A, Lee A, Gautam S. Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease. Acta Haematologica 2024, 148: 220-225. PMID: 39004080, PMCID: PMC12106121, DOI: 10.1159/000540239.Peer-Reviewed Original ResearchISTH DIC scoreFactor VIII levelsArea under the curveDIC scoreLiver diseaseFactor VIIIRetrospective chart review of patientsChart review of patientsCoagulopathy of liver diseaseReview of patientsRetrospective chart reviewCalculate area under the curveReceiver operating characteristic curveMultiple logistic regressionISTH scoreLaboratory parametersClinical challengeClinical utilityPatientsCharacteristic curveLab variablesLogistic regressionLiverDiseaseDiagnostic toolSafety Profile Comparison of 2 Smooth Tissue Expander Types
Almeida M, Alper D, Williams M, Shah R, Ihnat J, Hu K, Parikh N, Alperovich M. Safety Profile Comparison of 2 Smooth Tissue Expander Types. Annals Of Plastic Surgery 2024, 93: 178-182. PMID: 38980932, DOI: 10.1097/sap.0000000000004019.Peer-Reviewed Original ResearchConceptsBody mass indexComplication rateDrain durationMass indexAcellular dermal matrix useRetrospective review of patientsReview of patientsHigher body mass indexSmooth tissue expandersPain scoresChemotherapy exposureRetrospective reviewCapsular contractureSmooth implantsSafety profileWound breakdownFilling volumePatient comorbiditiesPerioperative informationCancer characteristicsMultivariate analysisComplicationsTissue expanderRadiation exposureMatrix useWhat Proportion of BRCA–Associated Breast Cancer Is Human Epidermal Growth Factor 2–Low and Eligible for Additional Targeted Therapy?
Forester E, Belsare A, Kim D, Whitaker K, Obeid E, Goldstein L, Bleicher R, Daly M, Williams A. What Proportion of BRCA–Associated Breast Cancer Is Human Epidermal Growth Factor 2–Low and Eligible for Additional Targeted Therapy? Journal Of Surgical Research 2024, 299: 217-223. PMID: 38776577, DOI: 10.1016/j.jss.2024.04.032.Peer-Reviewed Original ResearchTriple negative breast cancerHuman epidermal growth factor 2HER2-lowBreast cancerTargeted therapyMetachronous contralateral breast cancerPathogenic variantsHuman epidermal growth factor 2 statusBRCA-associated breast cancerRetrospective chart review of patientsChart review of patientsContralateral breast cancerBRCA gene statusInvasive breast cancerTargeted therapy optionsReview of patientsHR+/HER2- breast cancerRetrospective chart reviewNegative breast cancerFluorescence in situ hybridizationHER2 dataMetastatic settingTrastuzumab deruxtecanHER2-positiveGrowth factor 2Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy
Chakrani Z, Mellgard G, Saffran N, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 271-278. PMID: 38344754, DOI: 10.1097/coc.0000000000001087.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesReceptor-targeted therapyTreatment discontinuationSingle-institution retrospective review of patientsDiscontinued treatment due to toxicityTreatment discontinuation due to toxicityDiscontinued due to toxicityMultivariate analysisTreatment due to toxicityCastration-resistant prostate cancerSingle-institution retrospective reviewRetrospective review of patientsRisk of treatment discontinuationRisk factorsPatient-reported side effectsPatients discontinued treatmentTreatment-related toxicityEarly treatment discontinuationReview of patientsImprove survival outcomesDuration of treatmentLikelihood of treatment discontinuationProgression of diseaseTreatment toxicityThe Impact of Four Smoking Metrics on Survival After Diagnosis with HPV+ Oropharyngeal Cancer
Wilkins S, Shah R, Safranek C, Shah H, Mehra S. The Impact of Four Smoking Metrics on Survival After Diagnosis with HPV+ Oropharyngeal Cancer. The Laryngoscope 2024, 134: 3158-3164. PMID: 38294283, DOI: 10.1002/lary.31319.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaRecurrence-free survivalHPV+ oropharyngeal squamous cell carcinomaOverall survivalPack-yearsTobacco useRetrospective review of patientsImpact overall survivalReview of patientsSquamous cell carcinomaSmoking metricsInferior OSImpact of tobacco useMetastatic diseaseImpact of smokingPrognostic significanceRetrospective reviewCell carcinomaSmoking historyUnivariate analysisNever-smokersMultivariate analysisSmoking statusPatientsInclusion criteriaAbnormal uterine bleeding diagnoses and care following COVID-19 vaccination
Brooks N, Irving S, Kauffman T, Vesco K, Slaughter M, Smith N, Tepper N, Olson C, Weintraub E, Naleway A, Group V, DeNoble A, DeSilva M, Ellington S, Henninger M, Jazwa A, Kharbanda E, Lipkind H, Malden D, McNeil M, Tartof S, Zerbo O. Abnormal uterine bleeding diagnoses and care following COVID-19 vaccination. American Journal Of Obstetrics And Gynecology 2024, 230: 540.e1-540.e13. PMID: 38219855, DOI: 10.1016/j.ajog.2024.01.006.Peer-Reviewed Original ResearchAUB diagnosisAbnormal uterine bleedingAbnormal uterine bleeding casesUterine bleedingBleeding diagnosisAbnormal bleedingCOVID-19 vaccineChart reviewVaccinated patientsBleeding casesHealth system membersVaccination statusFemale patients of reproductive ageComparison of clinical characteristicsChart review of patientsPatients of reproductive ageProportion of Asian patientsDays of COVID-19 vaccinationReview of patientsVolume of bleedingProportion of patientsDemographic characteristics of patientsPost-COVID-19 vaccinationCharacteristics of patientsRace of patients
2022
Presentation of concurrent thrombotic thrombocytopenic purpura and Graves’ disease
Casasanta N, Shah N, Troy K, Edwards C, Patel R. Presentation of concurrent thrombotic thrombocytopenic purpura and Graves’ disease. Blood Coagulation & Fibrinolysis 2022, 33: 422-424. PMID: 35867945, DOI: 10.1097/mbc.0000000000001154.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraThrombocytopenic purpuraGraves' diseaseAutoimmune diseasesConcurrent thrombotic thrombocytopenic purpuraDeficient activity of ADAMTS13Retrospective review of patientsDiagnosing TTPUncontrolled autoimmune diseaseReview of patientsThyroid function testsAutoimmune thyroid diseaseActivity of ADAMTS13Thrombotic microangiopathyRetrospective reviewThyroid diseaseAutoimmune disordersStandard treatmentFunction testsDeficient activityPatientsThyrotoxicosisPurpuraDiseaseGravesPercutaneous mechanical thrombectomy and extracorporeal membranous oxygenation: A case series
Mously H, Hajjari J, Chami T, Hammad T, Schilz R, Carman T, Elgudin Y, Abu‐Omar Y, Pelletier M, Shishehbor M, Li J. Percutaneous mechanical thrombectomy and extracorporeal membranous oxygenation: A case series. Catheterization And Cardiovascular Interventions 2022, 100: 274-278. PMID: 35686535, DOI: 10.1002/ccd.30295.Peer-Reviewed Original ResearchConceptsPulmonary Embolism Response TeamExtracorporeal membrane oxygenationPulmonary embolismFollow-up periodCardiac arrestPulmonary embolism response team activationHigh-risk pulmonary embolismRetrospective chart review of patientsChart review of patientsExtracorporeal membrane oxygenation initiationMassive pulmonary embolismMedian ECMO durationReview of patientsRight heart strainRetrospective chart reviewSignificant hemodynamic compromisePERT programsLife-threatening diagnosisMassive PEECMO durationMedian agePE diagnosisHemodynamic compromiseSignificant morbidityHeart strainSurvival in total preoperative verus perioperative chemotherapy for patients with metastatic high-grade appendiceal adenocarcinoma undergoing CRS/HIPEC.
Morgan R, Yan A, Dhiman A, Sood D, Ong C, Wu X, Shergill A, Polite B, Turaga K, Eng O. Survival in total preoperative verus perioperative chemotherapy for patients with metastatic high-grade appendiceal adenocarcinoma undergoing CRS/HIPEC. Journal Of Clinical Oncology 2022, 40: 90-90. DOI: 10.1200/jco.2022.40.4_suppl.090.Peer-Reviewed Original ResearchPeri-operative groupPre-operative groupChemotherapy-related toxicityAppendiceal cancerAppendiceal adenocarcinomaPeritoneal metastasisHigh-grade appendiceal adenocarcinomaHigh-grade appendiceal cancerMonths of systemic chemotherapyOptimal timing of chemotherapyRetrospective review of patientsSignet ring cell histologyAssociated with similar survivalPlanned 6 monthsMedian overall survivalHyperthermic intraperitoneal chemotherapyPre-operative chemotherapyPoorly differentiated tumorsTiming of chemotherapyPeri-operative treatmentReview of patientsTertiary referral centerColon cancer patientsCytoreductive surgeryCell histology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply